The median plasma NT‐proBNP concentration in dogs with AP in phase II of this study was greater than the plasma NT‐proBNP (445 pmol/L) diagnostic cut‐off proposed to discriminate dogs with mitral valve disease or dilated cardiomyopathy (DCM) from healthy dogs.24 This evidence concerns the gene NPPB and dilated cardiomyopathy.